International Journal of Medical Biochemistry (May 2022)

Circulating sTWEAK and its scavenger receptor sCD163 concentrations in patients with Behçet's disease

  • Fulya Balaban Yücesan,
  • Asım Örem,
  • Deniz Aksu Arıca,
  • Burak Akşan,
  • Serap Özer Yaman,
  • Buket Akcan,
  • Birgül Kural,
  • Sevgi Bahadır

DOI
https://doi.org/10.14744/ijmb.2022.98700
Journal volume & issue
Vol. 5, no. 2
pp. 89 – 95

Abstract

Read online

INTRODUCTION: Behçet's disease (BD) is a chronic multisystemic inflammatory disorder and is associated with many inflammatory processes. The present study aimed to examine the serum levels of proinflammatory cytokine soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) and its scavenger receptor soluble cluster of differentiation 163 (sCD163) simultaneously in patients with BD by considering their relationships with disease activity. METHODS: The study group included 53 patients with BD (29 females and 24 males) and 30 healthy individuals. Patients with a lesion or active organ involvement were defined as active (n=39) and those without were identified as inactive (n=14). Serum sTWEAK and sCD163 concentrations were determined by enzyme-linked immunosorbent assay. RESULTS: Serum sTWEAK and sCD163 levels were significantly increased in patients with BD compared with the healthy group (p=0.016 and p=0.003, respectively). Concentrations of these two molecules were also higher in active and inactive BD than the healthy individuals (p=0.043 for sTWEAK and p=0.010 for sCD163). Receiver operating characteristic curve analysis revealed that serum sCD163 and sTWEAK levels had a discriminating ability between patients with BD and healthy controls with area under the curve values of 0.706 and 0.661, respectively. DISCUSSION AND CONCLUSION: It was concluded that circulating sTWEAK and its scavenger receptor sCD163 levels were increased in BD, significantly predicted the disease, and might be significant molecules to assess inflammation.

Keywords